NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its Board of Directors has approved a stock repurchase plan on Tuesday, April 24th 2018, which allows the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 18.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.

Waters Co. (NYSE:WAT) issued its quarterly earnings data on Tuesday, April, 24th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier earned $530.70 million during the quarter, compared to analyst estimates of $534.17 million. Waters had a return on equity of 25.80% and a net margin of 1.14%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $1.46 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19.

17 analysts have issued twelve-month target prices for Waters' stock. Their forecasts range from $180.00 to $230.00. On average, they expect Waters' stock price to reach $206.5333 in the next year. View Analyst Ratings for Waters.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class B (BIO.B), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Press coverage about WAT stock has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Waters earned a daily sentiment score of 0.18 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 45.89 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Waters' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.20%), Massachusetts Financial Services Co. MA (6.33%), Baillie Gifford & Co. (3.29%), Veritas Asset Management LLP (2.50%), Northern Trust Corp (1.38%) and Franklin Resources Inc. (1.14%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Veritas Asset Management LLP, Baillie Gifford & Co., Schroder Investment Management Group, Boston Partners, Millennium Management LLC, Swiss National Bank and American Century Companies Inc.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Citigroup Inc., Bamco Inc. NY, Summit Trail Advisors LLC, JPMorgan Chase & Co., Royal Bank of Canada, Ontario Teachers Pension Plan Board and Champlain Investment Partners LLC. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $194.14.

Waters has a market capitalization of $15.35 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]